Literature DB >> 15696024

Angiogenesis and its role in colorectal tumor and metastasis formation.

Lee M Ellis1.   

Abstract

Advances in our comprehension of cancer biology and metastasis formation have led to the development of new therapeutic approaches that target tumor biology. The survival and establishment of metastatic lesions depend on a shift in the normal balance of key regulatory factors in favor of angiogenesis. Although a number of these factors have been identified, the most potent regulator of angiogenesis is vascular endothelial growth factor (VEGF). In phase I trials, targeting VEGF with single-agent therapy did not produce clinical benefit for patients, despite promise in preclinical trials. However, the recent data showing that anti-VEGF therapy can enhance the effects of chemotherapy demonstrate the utility in targeting angiogenic factors as a component of antineoplastic regimens. A better understanding of the functions of VEGF allows the development of new hypotheses with regard to its mechanism of action. This article will highlight what is known about colorectal cancer angiogenesis, and will discuss how therapy targeting VEGF may enhance the effects of chemotherapy (and radiation therapy).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15696024     DOI: 10.1053/j.seminoncol.2004.11.028

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  13 in total

1.  Dovitinib (TKI258), a multi-target angiokinase inhibitor, is effective regardless of KRAS or BRAF mutation status in colorectal cancer.

Authors:  Choong-Kun Lee; Myung Eun Lee; Won Suk Lee; Jeong Min Kim; Kyu Hyun Park; Tae Soo Kim; Kang Young Lee; Joong Bae Ahn; Hyun Cheol Chung; Sun Young Rha
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

2.  Genetic and pathologic changes associated with lymphovascular invasion of colorectal adenocarcinoma.

Authors:  Jin C Kim; Seon A Roh; Kang H Lee; Hwan Namgung; Jung R Kim; Jung S Kim
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

3.  Expression of KAI1 and tenascin, and microvessel density are closely correlated with liver metastasis of gastrointestinal adenocarcinoma.

Authors:  Huachuan Zheng; Koichi Tsuneyama; Chunmei Cheng; Hiroyuki Takahashi; Zhengguo Cui; Kazuhiro Nomoto; Yoshihiro Murai; Yasuo Takano
Journal:  J Clin Pathol       Date:  2006-05-12       Impact factor: 3.411

4.  FOXQ1 mediates the crosstalk between TGF-β and Wnt signaling pathways in the progression of colorectal cancer.

Authors:  Xudong Peng; Zan Luo; Qingjie Kang; Dawei Deng; Qiang Wang; Hongxia Peng; Shan Wang; Zhengqiang Wei
Journal:  Cancer Biol Ther       Date:  2015-05-08       Impact factor: 4.742

5.  The role of anti-VEGF agents in the treatment of advanced gastric cancer: a meta-analysis of randomized controlled trials.

Authors:  Wei-Xiang Qi; Zan Shen; Li-Na Tang; Yang Yao
Journal:  Tumour Biol       Date:  2014-05-07

6.  [Feasibility of targeted therapy based on immunohistochemical expression analysis in androgen-independent prostate cancer].

Authors:  C-H Ohlmann; E Markert; M Gerharz; D Pfister; H-P Dienes; U Engelmann; A Heidenreich
Journal:  Urologe A       Date:  2008-09       Impact factor: 0.639

Review 7.  Management of regorafenib-related toxicities: a review.

Authors:  Saravanan K Krishnamoorthy; Valerie Relias; Sunit Sebastian; Vijay Jayaraman; Muhammad Wasif Saif
Journal:  Therap Adv Gastroenterol       Date:  2015-09       Impact factor: 4.409

Review 8.  Therapeutic potential of TAS-102 in the treatment of gastrointestinal malignancies.

Authors:  Godefridus J Peters
Journal:  Ther Adv Med Oncol       Date:  2015-11       Impact factor: 8.168

9.  Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours.

Authors:  D Strumberg; B Schultheis; I A Adamietz; O Christensen; M Buechert; J Kraetzschmar; P Rajagopalan; M Ludwig; A Frost; S Steinbild; M E Scheulen; K Mross
Journal:  Br J Cancer       Date:  2008-11-18       Impact factor: 7.640

Review 10.  Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.

Authors:  Salvatore Siena; Andrea Sartore-Bianchi; Federica Di Nicolantonio; Julia Balfour; Alberto Bardelli
Journal:  J Natl Cancer Inst       Date:  2009-09-08       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.